|Poll|August 21, 2014

Mini-quiz: Electroencephalogram Abnormalities in Psychiatric Patients

Compared with healthy controls, is the prevalence of EEG abnormalities in psychiatric patients different than in healthy controls? Take the quiz and learn more.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

ByErica Taylor, MD, MPH,Drew Cumming, MD,James A. Bourgeois, OD, MD

October 24th 2025

Dr Max Fink, Farewell and Thank You

ByHoracio A. Capote, MD

October 16th 2025

Addressing Cognition in Late-Life Depression

ByJoshua J. Hubregsen, MD,Andre R. Brunoni, MD, PhD,Molly E. Camp, MD,Tarek K. Rajji, MD

October 1st 2025

Dr Max Fink, Farewell and Thank You!

ByHoracio A. Capote, MD

August 27th 2025

The Double-Edged Sword of Affluence

ByDanielle Egbe, DO,Christina B. Smith, MD

May 12th 2025

Latest CME

Video

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mini-quiz: Electroencephalogram Abnormalities in Psychiatric Patients

Newsletter

Related Content

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

Dr Max Fink, Farewell and Thank You

Addressing Cognition in Late-Life Depression

Dr Max Fink, Farewell and Thank You!

The Double-Edged Sword of Affluence

Latest CME

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Survival Guide For Human Therapists In A Chatbot World

sNDA Submitted for AXS-05 for the Treatment of Alzheimer Disease Agitation

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

Spilling The Beans About Fava Beans, A Sequel: Fava Bean Abuse

Poll: Has the Shortage of IV Ativan Impacted Your Practice?